Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cerecor Inc. stock logo
CERC
Cerecor
$10.85
-5.6%
$2.60
$1.98
$4.50
$1.04B1.441.27 million shs57,346 shs
Chiasma, Inc. stock logo
CHMA
Chiasma
$3.76
$4.01
$2.77
$5.74
$217.68M1.282.12 million shs147 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$6.70
-1.5%
$6.49
$4.00
$8.69
$85.10M0.833,782 shs40,291 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.53
+4.8%
$1.40
$1.26
$2.66
$75.04M0.748,303 shs30,460 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cerecor Inc. stock logo
CERC
Cerecor
0.00%-26.69%-18.99%+150.64%+352.90%
Chiasma, Inc. stock logo
CHMA
Chiasma
0.00%0.00%0.00%0.00%0.00%
LifeVantage Co. stock logo
LFVN
LifeVantage
+2.41%+11.29%+11.11%+2.87%+60.76%
MediciNova, Inc. stock logo
MNOV
MediciNova
+8.15%+5.80%-2.01%+3.18%-34.53%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
2.0773 of 5 stars
0.03.01.72.72.61.71.3
MediciNova, Inc. stock logo
MNOV
MediciNova
0.3005 of 5 stars
0.04.00.00.02.30.80.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cerecor Inc. stock logo
CERC
Cerecor
$6.70M155.48N/AN/A$0.22 per share49.32
Chiasma, Inc. stock logo
CHMA
Chiasma
$1.11M196.11N/AN/A$1.59 per share2.36
LifeVantage Co. stock logo
LFVN
LifeVantage
$205.45M0.41$0.53 per share12.67$2.71 per share2.47
MediciNova, Inc. stock logo
MNOV
MediciNova
$1M75.04N/AN/A$1.27 per share1.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cerecor Inc. stock logo
CERC
Cerecor
-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/A
Chiasma, Inc. stock logo
CHMA
Chiasma
-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.54M$0.2823.93N/A1.75%27.02%12.42%8/26/2024 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$8.56M-$0.17N/AN/AN/AN/A-13.19%-12.50%8/14/2024 (Estimated)

Latest LFVN, MNOV, CERC, and CHMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/15/2024Q4 2023
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.08-$0.04+$0.04-$0.04N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.162.39%N/A57.14%1 Years
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A

Latest LFVN, MNOV, CERC, and CHMA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2024
LifeVantage Co. stock logo
LFVN
LifeVantage
Quarterly$0.042.44%5/31/20245/31/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cerecor Inc. stock logo
CERC
Cerecor
0.79
2.19
2.18
Chiasma, Inc. stock logo
CHMA
Chiasma
N/A
7.91
7.08
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.68
1.01
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
15.61
15.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cerecor Inc. stock logo
CERC
Cerecor
62.84%
Chiasma, Inc. stock logo
CHMA
Chiasma
61.68%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%

Insider Ownership

CompanyInsider Ownership
Cerecor Inc. stock logo
CERC
Cerecor
45.70%
Chiasma, Inc. stock logo
CHMA
Chiasma
8.30%
LifeVantage Co. stock logo
LFVN
LifeVantage
6.76%
MediciNova, Inc. stock logo
MNOV
MediciNova
16.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cerecor Inc. stock logo
CERC
Cerecor
3196.01 millionN/ANot Optionable
Chiasma, Inc. stock logo
CHMA
Chiasma
8557.89 millionN/ANot Optionable
LifeVantage Co. stock logo
LFVN
LifeVantage
24812.70 million11.84 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1349.05 million40.76 millionOptionable

LFVN, MNOV, CERC, and CHMA Headlines

SourceHeadline
MediciNova: Q1 Earnings SnapshotMediciNova: Q1 Earnings Snapshot
wtop.com - May 9 at 9:41 PM
MediciNova, Inc.: MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)MediciNova, Inc.: MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
finanznachrichten.de - May 7 at 9:10 AM
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
globenewswire.com - May 7 at 6:00 AM
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)
americanbankingnews.com - May 7 at 3:40 AM
MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years agoMediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years ago
finance.yahoo.com - April 30 at 8:40 AM
MediciNova, Inc. (NASDAQ:MNOV) Short Interest Down 26.0% in AprilMediciNova, Inc. (NASDAQ:MNOV) Short Interest Down 26.0% in April
marketbeat.com - April 27 at 7:20 AM
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
globenewswire.com - April 2 at 7:00 PM
MediciNova, Inc.: MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMediciNova, Inc.: MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
finanznachrichten.de - March 27 at 1:30 PM
Pre-market Movers: IBIO, DRCT, NUVB, PAYS, LUXH…Pre-market Movers: IBIO, DRCT, NUVB, PAYS, LUXH…
msn.com - March 27 at 8:30 AM
MediciNova Gets Patent in Japan for Multiple Sclerosis-Related TreatmentMediciNova Gets Patent in Japan for Multiple Sclerosis-Related Treatment
marketwatch.com - March 27 at 8:30 AM
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
tmcnet.com - March 27 at 8:30 AM
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
globenewswire.com - March 26 at 7:00 PM
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis SocietyMediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
globenewswire.com - March 20 at 7:00 PM
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In GrowthCompanies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
finance.yahoo.com - March 20 at 6:11 PM
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of ToxicologyMediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
globenewswire.com - March 12 at 6:30 AM
MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…
finance.yahoo.com - February 29 at 2:54 PM
Medicinova IncMedicinova Inc
money.usnews.com - February 28 at 6:13 PM
MediciNova, Inc.: MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaMediciNova, Inc.: MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
finanznachrichten.de - January 17 at 12:09 PM
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaMediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
finance.yahoo.com - January 17 at 7:08 AM
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of ToxicologyMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
finance.yahoo.com - December 21 at 7:32 PM
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast)MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast)
eagletribune.com - December 7 at 7:53 AM
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
markets.businessinsider.com - December 6 at 7:58 PM
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
finance.yahoo.com - December 6 at 7:58 PM
MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…
finance.yahoo.com - November 27 at 1:15 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cerecor logo

Cerecor

NASDAQ:CERC
Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Chiasma logo

Chiasma

NASDAQ:CHMA
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
LifeVantage logo

LifeVantage

NASDAQ:LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.
MediciNova logo

MediciNova

NASDAQ:MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.